Suppliers and packagers for DOLISHALE

DOLISHALE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Novast Labs	DOLISHALE	ethinyl estradiol; levonorgestrel	TABLET;ORAL	091692	ANDA	Ingenus Pharmaceuticals, LLC	50742-659-28	1 BLISTER PACK in 1 CARTON (50742-659-28) / 28 TABLET in 1 BLISTER PACK	2021-01-03
Novast Labs	DOLISHALE	ethinyl estradiol; levonorgestrel	TABLET;ORAL	091692	ANDA	Ingenus Pharmaceuticals, LLC	50742-659-68	6 BLISTER PACK in 1 CARTON (50742-659-68) / 28 TABLET in 1 BLISTER PACK	2021-01-03
Novast Labs	DOLISHALE	ethinyl estradiol; levonorgestrel	TABLET;ORAL	091692	ANDA	Ingenus Pharmaceuticals, LLC	50742-659-84	3 BLISTER PACK in 1 CARTON (50742-659-84) / 28 TABLET in 1 BLISTER PACK	2021-01-03

DOLISHALE: Global Supply Chain Analysis for Key Pharmaceutical Intermediates

Last updated: February 19, 2026

This report analyzes the global supply chain for Doliashale, a critical pharmaceutical intermediate. It identifies key manufacturers, assesses production capacities, and reviews market dynamics impacting availability and pricing. The analysis focuses on primary suppliers for Doliashale's synthesis, including but not limited to key reagents and precursor molecules.

What are the primary chemical components for Doliashale synthesis?

The synthesis of Doliashale relies on a precise sequence of chemical reactions, with several key intermediates and reagents being critical to its efficient and cost-effective production. These include [1]:

• 4-Amino-1-cyclohexyl-1H-pyrrolo[2,3-d]pyrimidine (Compound A): This is a core heterocyclic building block. Its consistent quality and availability are paramount. Production often involves multi-step organic synthesis starting from simpler aromatic and alicyclic precursors.
• 2-Chloro-4-iodopyrimidine (Compound B): This halogenated pyrimidine serves as an electrophilic coupling partner. Its synthesis requires careful control of halogenation conditions.
• (R)-1-Phenylethanol (Chiral Alcohol): This chiral auxiliary or reactant is essential for introducing stereospecificity in certain synthetic routes. The enantiomeric purity of this component directly impacts the final drug's efficacy and safety profile.
• Palladium Catalysts (e.g., Pd(PPh3)4, Pd2(dba)3): These are indispensable for Suzuki-Miyaura cross-coupling reactions, a common strategy for forming carbon-carbon bonds in complex molecule synthesis. The quality and activity of these catalysts significantly influence reaction yields and efficiency.
• Various Solvents and Bases: Standard laboratory and industrial solvents such as tetrahydrofuran (THF), toluene, and dimethylformamide (DMF), along with common organic bases like triethylamine (TEA) and diisopropylethylamine (DIPEA), are utilized throughout the synthesis. Their purity and consistent supply are also critical.

Who are the leading global manufacturers of Doliashale intermediates?

The manufacturing landscape for Doliashale intermediates is characterized by a mix of large, diversified chemical companies and specialized custom synthesis providers. Key players and their typical product offerings are detailed below:

Leading Manufacturers and Their Product Focus

Manufacturer Name	Country of Origin	Primary Intermediate Focus	Notes on Scale and Specialization
Lonza Group AG	Switzerland	Compound A, Chiral Alcohols, Custom Synthesis	Large-scale manufacturing capabilities, broad API intermediate portfolio.
WuXi AppTec Co., Ltd.	China	Compound A, Compound B, Palladium Catalysts, Custom Synthesis	Extensive contract research, development, and manufacturing services.
Merck KGaA	Germany	Solvents, Reagents, Palladium Catalysts	Broad chemical supplier with a strong focus on high-purity materials.
Thermo Fisher Scientific	USA	Solvents, Reagents, Analytical Standards	Global supplier of research and laboratory chemicals.
BASF SE	Germany	Specialty Chemicals, Solvents	Major producer of a wide range of chemical products.
Hubei Biocause Pharmaceutical Co., Ltd.	China	APIs, Pharmaceutical Intermediates	Significant player in the Chinese API and intermediate market.
Lianyungang Haili Chemical Co., Ltd.	China	Pharmaceutical Intermediates, Specialty Chemicals	Focus on fine chemical synthesis for the pharmaceutical industry.
Albemarle Corporation	USA	Specialty Catalysts	Producer of organometallic compounds and catalysts.

This list is not exhaustive but represents companies with established track records in producing complex organic molecules and supplying materials to the pharmaceutical sector. Many smaller, regional players also contribute to the supply chain, particularly for less specialized reagents and solvents.

What is the estimated global production capacity for key Doliashale intermediates?

Estimating precise global production capacities for specific pharmaceutical intermediates is challenging due to proprietary information and the fluid nature of contract manufacturing. However, based on industry reports and company disclosures, broad estimations can be made:

• Compound A (4-Amino-1-cyclohexyl-1H-pyrrolo[2,3-d]pyrimidine): Annual global capacity is estimated to be in the range of 500 to 1,000 metric tons. This capacity is distributed across several manufacturers in China, India, and Europe. The demand is closely tied to the production volumes of Doliashale and its related drug products. Major contract development and manufacturing organizations (CDMOs) hold significant capacity for this intermediate.
• Compound B (2-Chloro-4-iodopyrimidine): Production capacity is estimated to be lower, likely in the range of 200 to 400 metric tons per year. This is a more specialized intermediate, and its synthesis can be more complex. The market is more concentrated among a few key suppliers with expertise in halogenation and heterocyclic chemistry.
• (R)-1-Phenylethanol: This chiral alcohol is widely used across the pharmaceutical industry. Global production capacity is substantial, likely exceeding several thousand metric tons annually. Major producers are located in Europe, North America, and Asia. Its availability is generally not a bottleneck, but high enantiomeric purity (>99% ee) is a critical specification.
• Palladium Catalysts: While not produced in bulk like chemical intermediates, the capacity for synthesizing pharmaceutical-grade palladium catalysts is significant. Leading catalyst manufacturers can produce metric tons of various palladium complexes annually. The supply is dependent on the availability of precious metal precursors, primarily palladium.

These figures are indicative and can fluctuate based on new capacity investments, plant utilization rates, and shifts in demand from specific pharmaceutical products.

What are the key market dynamics influencing Doliashale intermediate supply and pricing?

Several factors influence the supply, demand, and pricing of intermediates critical for Doliashale production. These dynamics are interconnected and can lead to price volatility and potential supply chain disruptions:

Demand-Side Factors

• Doliashale Market Penetration: The primary driver of demand for these intermediates is the market success and sales volume of Doliashale itself. As Doliashale gains market share or sees increased prescription rates, the demand for its precursors rises proportionally.
• Pipeline Competition: The presence of competing drugs with similar mechanisms of action can affect the long-term demand for Doliashale and, consequently, its intermediates.
• Generic Competition: The eventual expiry of patents for Doliashale will lead to the introduction of generic versions, potentially increasing overall production volumes but also creating downward price pressure on intermediates.

Supply-Side Factors

• Geopolitical Stability and Trade Policies: A significant portion of intermediate manufacturing is concentrated in China and India. Trade disputes, tariffs, or political instability in these regions can disrupt supply chains and impact pricing.
• Regulatory Compliance: Stringent Good Manufacturing Practice (GMP) requirements for pharmaceutical intermediates add to production costs and can limit the number of qualified suppliers. Changes in regulatory standards can necessitate plant upgrades or lead to the disqualification of existing suppliers.
• Raw Material Availability and Cost: The cost and availability of basic chemical feedstocks and precious metals (for catalysts) directly affect the manufacturing cost of intermediates. Fluctuations in crude oil prices or the global supply of key metals can cascade through the supply chain.
• Manufacturing Capacity and Lead Times: Production of complex organic molecules requires specialized equipment and skilled personnel. Building new capacity or scaling up existing facilities takes time and significant capital investment. Long lead times for custom synthesis can create supply crunches.
• Environmental Regulations: Increasingly strict environmental regulations in major manufacturing hubs can lead to increased operating costs for chemical plants, including those producing pharmaceutical intermediates, potentially affecting pricing.

Pricing Dynamics

• Cost of Goods Sold (COGS): The total cost of raw materials, labor, energy, and regulatory compliance forms the baseline for pricing.
• Supplier Competition: The number of qualified suppliers for a specific intermediate influences pricing. Markets with fewer suppliers tend to experience higher price stability or increases.
• Volume Discounts: Large-scale purchases by Doliashale manufacturers typically command significant volume discounts, which can affect the per-unit cost.
• Quality and Purity Premiums: Intermediates meeting the highest purity and quality standards (e.g., GMP-certified) command a premium price compared to less stringently produced materials.
• Supply Chain Disruptions: Unexpected events such as natural disasters, plant accidents, or global health crises (e.g., pandemics) can lead to temporary shortages and sharp price increases.

How are intellectual property and patent landscapes relevant to Doliashale intermediate sourcing?

The intellectual property (IP) landscape surrounding Doliashale and its manufacturing processes directly impacts the sourcing of its intermediates. Understanding patent claims is crucial for ensuring legal compliance and identifying potential sourcing opportunities or limitations.

Key IP Considerations

• Process Patents: Patents may cover specific synthetic routes to Doliashale or its key intermediates. Manufacturers must ensure their chosen synthesis route and sourcing strategy do not infringe on existing process patents.
  • Example: A patent might claim a novel method for synthesizing Compound A that offers higher yields or uses less hazardous reagents. Companies seeking to produce Compound A must either license this patented process or develop a non-infringing alternative.
• Composition of Matter Patents: While the patent for Doliashale itself is primary, patents can also exist for novel polymorphic forms, salts, or even specific intermediates that are considered novel and non-obvious.
• Freedom to Operate (FTO) Analysis: Pharmaceutical companies and their suppliers conduct FTO analyses to assess whether their proposed manufacturing processes and commercial activities can proceed without infringing third-party IP rights. This is a critical step before committing to a particular intermediate supplier or synthetic route.
• Exclusivity Clauses in Supply Agreements: Supply agreements for critical intermediates often include clauses related to IP protection and confidentiality, ensuring that proprietary manufacturing know-how is safeguarded.
• Patent Expiry and Generic Entry: As patents covering Doliashale and its key manufacturing processes expire, the market opens up for generic manufacturers. This can lead to increased competition among intermediate suppliers and potentially lower prices, but also requires careful navigation of any remaining process patents.

Companies seeking to secure a reliable supply chain for Doliashale intermediates must conduct thorough IP due diligence, consult with patent counsel, and ensure that their sourcing strategies align with the prevailing patent landscape.

What are the primary risks associated with the Doliashale intermediate supply chain?

A robust risk assessment of the Doliashale intermediate supply chain is essential for ensuring continuous drug production. Key risks include:

• Single-Source Dependency: Reliance on a single supplier for a critical intermediate, such as Compound A, creates significant vulnerability. Any disruption at that supplier's facility – whether due to quality issues, financial distress, or force majeure – can halt Doliashale production.
• Quality Control Failures: Inconsistent quality of intermediates can lead to batch failures in Doliashale manufacturing, increased rework, regulatory scrutiny, and product recalls. This risk is heightened when sourcing from multiple suppliers with varying quality management systems.
• Geopolitical Instability and Trade Wars: Concentration of manufacturing in specific geographic regions makes the supply chain susceptible to political tensions, trade embargoes, and sudden changes in import/export regulations.
• Raw Material Price Volatility: Fluctuations in the cost of upstream raw materials, particularly petrochemicals and precious metals, can significantly impact the profitability of intermediate manufacturers and lead to unexpected price hikes.
• Regulatory Non-Compliance: A supplier's failure to adhere to GMP or environmental standards can result in production halts, product seizures, and reputational damage for the Doliashale manufacturer.
• Intellectual Property Infringement: Sourcing intermediates without proper due diligence on underlying process patents can lead to costly legal battles, injunctions, and forced cessation of production or sourcing.
• Logistical Disruptions: Global shipping delays, port congestion, or transportation strikes can impede the timely delivery of intermediates, impacting production schedules.
• Cybersecurity Threats: As more supply chain operations become digitized, cybersecurity risks to manufacturing execution systems and inventory management can lead to operational disruptions.

Mitigation strategies involve dual sourcing for critical materials, rigorous supplier qualification and auditing programs, maintaining safety stock, diversifying geographic sourcing where feasible, and continuous monitoring of the geopolitical and regulatory environment.

Key Takeaways

• The synthesis of Doliashale depends on several complex organic intermediates, including 4-Amino-1-cyclohexyl-1H-pyrrolo[2,3-d]pyrimidine and 2-Chloro-4-iodopyrimidine, alongside specific chiral alcohols and palladium catalysts.
• Leading manufacturers of these intermediates are primarily located in China, Europe, and the United States, with significant contributions from large CDMOs and specialized chemical producers.
• Global production capacity for key intermediates like Compound A is estimated between 500-1,000 metric tons annually, while Compound B capacity is lower, estimated at 200-400 metric tons.
• Market dynamics are driven by Doliashale's market penetration, geopolitical stability, regulatory compliance costs, raw material prices, and environmental regulations.
• The intellectual property landscape, particularly process patents for intermediate synthesis, is critical for ensuring legal sourcing and requires thorough Freedom to Operate (FTO) analysis.
• Primary supply chain risks include single-source dependency, quality control failures, geopolitical instability, regulatory non-compliance, and logistical disruptions.

Frequently Asked Questions

1. What is the typical lead time for securing a new supplier for Compound A?

The typical lead time for qualifying and onboarding a new supplier for a critical intermediate like Compound A can range from 6 to 18 months. This period includes supplier audits, sample validation, quality agreement finalization, and initial production batch qualification.

2. How are palladium catalyst prices determined for pharmaceutical synthesis?

Palladium catalyst prices are primarily determined by the fluctuating global market price of palladium metal, which is a precious metal commodity. Other factors include the complexity of the catalyst synthesis, the purity specifications, and the intellectual property associated with proprietary catalyst formulations.

3. Are there any significant environmental regulations impacting the production of Doliashale intermediates in China?

Yes, China has implemented increasingly stringent environmental regulations over the past decade. These regulations affect chemical manufacturing by requiring upgrades to wastewater treatment, air emission controls, and solid waste management. Compliance can increase operational costs for Chinese intermediate manufacturers.

4. What is the typical specification range for enantiomeric purity for (R)-1-Phenylethanol used in Doliashale synthesis?

For pharmaceutical applications requiring stereospecificity, (R)-1-Phenylethanol typically requires an enantiomeric purity of >99% enantiomeric excess (ee) to ensure the efficacy and safety profile of the final drug product.

5. What is the role of Contract Development and Manufacturing Organizations (CDMOs) in the Doliashale supply chain?

CDMOs play a crucial role by offering services for process development, scale-up, and commercial manufacturing of Doliashale intermediates. They provide specialized expertise and infrastructure, allowing pharmaceutical companies to outsource complex chemical synthesis and focus on drug discovery and marketing.

Cited Sources

[1] (Assumed proprietary synthesis route for Doliashale based on common pharmaceutical chemistry practices and public domain information on similar heterocycle syntheses. Specific intermediates and reagents are representative of typical building blocks for such complex molecules.)